Sign up to save your podcasts
Or
Share Endocrine Therapies in ER-Positive/HER2-Negative MBC: Understanding Their Benefits and Limitations to Optimize Treatment Selection
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Endocrine Therapies in ER-Positive/HER2-Negative MBC: Understanding Their Benefits and Limitations to Optimize Treatment Selection
Did you know that approximately 50% of breast cancer patients who have been exposed to an aromatase inhibitor (AI) over time in the metastatic setting develop an ESR1 mutation?
Credit available for this activity expires: 10/17/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1003008?ecd=bdc_podcast_libsyn_mscpedu
View all episodes
By Medscape
4.3
2323 ratings
Did you know that approximately 50% of breast cancer patients who have been exposed to an aromatase inhibitor (AI) over time in the metastatic setting develop an ESR1 mutation?
Credit available for this activity expires: 10/17/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1003008?ecd=bdc_podcast_libsyn_mscpedu
More shows like Keeping Current CME
View all
NEJM This Week
318 Listeners
AFP: American Family Physician Podcast
696 Listeners
JAMA Clinical Reviews
495 Listeners
JACC This Week
170 Listeners
Diabetes Core Update
101 Listeners
This Week in Cardiology
887 Listeners
The Bob Harrington Show
13 Listeners
One-on-One with Eric Topol
17 Listeners
Mayo Clinic Talks
290 Listeners
Frankly Speaking About Family Medicine
263 Listeners
The Curbsiders Internal Medicine Podcast
3,338 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
139 Listeners
Core IM | Internal Medicine Podcast
1,153 Listeners
The Peter Attia Drive
8,782 Listeners
Annals On Call Podcast
195 Listeners
Medicine and the Machine
61 Listeners
Keeping Current
8 Listeners
Cardionerds: A Cardiology Podcast
430 Listeners
The Cribsiders
314 Listeners